Lipoprotein (a) as a risk factor of ischemic stroke: a case-control study

Prashant Pramod More, Bhushan Jayant Itkelwar, Dilip Ratan Patil


Background: Undoubtedly, stroke is an important public health problem as well as an important precursor of mortality and morbidity. It also leads to loss of disability adjusted life years as it causes long term severe disability. The objective of this study was to study association of lipoprotein (a) in ischemic stroke patients with matched controls.

Methods: This is a prospective case controlled study. The study group includes 100 stroke patients consecutive admitted in medicine/neurology departments of our hospital, and 50 patients as control group admitted for nonvascular diseases. The ethical committee clearance was obtained from the appropriate authority appointed by the institution. Detailed history taking and neurological examination were done in all patients

Results: This case-control study shows that ischemic stroke patients have higher levels of Lp (a) as compared to that of controls. Thus, people with high Lp (a) levels may have higher predilection for developing ischemic stroke. Lp (a) levels do not correspond to stroke severity stroke in our study. Thus, higher Lp (a) levels do not lead to more severe type of stroke. Lp (a) levels do not correlate with the outcome of stroke, hence Lp (a) level may not be a good indicator for assessing prognosis or predicting mortality

Conclusions: This case-control study shows that ischemic stroke patients have higher levels of Lp (a) as compared to that of controls. Thus, people with high Lp (a) levels may have higher predilection for developing ischemic stroke factors for stroke like diabetes, smoking and hypertension do not predisposed to higher Lp (a).


Case control study, Lp (a) levels, Renal function, Risk factors

Full Text:



American Heart Association. Heart and stroke facts: 1994 Statistical supplement. Dallas: American Heart Association, 1993.

Warlow C. Burden of stroke. In: Donaghy M, editor. Brain’s disease of the nervous system, 11th ed. New York: Oxford University Press; 2001:777.

West of Scotland Coronary Prevention Study Group. West of Scotland coronary prevention study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet. 1996;348:1339-2.

The pravastatin multinational study group for cardiac risk patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/l plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-7.

Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4 S). Lancet. 1994;344:1383-9.

Dahlen G. Lp (a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994;108:111-26.

Konemari G. Lipoprotein (a) and other risk factors for cerebral infarction. Hiroshima J Med Sci. 1995;44:65-77.

Mc Lean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature. 1987;330(6144):132-7.

Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature. 1989;339(6222):301-3.

DeGraba TJ, Hallenbeck JM, Pettigrew KD, Dutka AJ, Kelly BJ. Progression in acute stroke. Stroke. 1999;30(6):1208-12.

Rankin L. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957;2:200-15.

Sulter G, Steen C, De KJ. Use of the Barthel index and modified Rankin Scale in acute stroke trials. Stroke. 1999;30:1538-41.

Jurgens G, Koltringer P. Lipoprotein (a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurol. 1987;37:513-15.

Nagayama M, Shinohara Y, Nagayama T. Lipoprotein (a) and ischemic cerebrovascular disease in young adults. Stroke. 1994;25:74-8.

Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein (a) levels are an independent risk factor for cerebral infarction. Stroke. 1993;24(7):965-9.

Pedro-Botet J, Senti M, Nogues X, Rubiés-Prat J, Roquer J, D'olhaberriague L, et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein (a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke. 1992;23(11):1556-62.

Asplund K, Olsson T, Viitanen M, Dahlén G. Lp (a) lipoprotein in patients with acute stroke. Cerebrovascular Diseases. 1991;1(2):90-6.

Kooten FV, Krimpen JV, Dippel DW, Hoogerbrugge N, Koudstaal PJ. Lipoprotein (a) in patients with acute cerebral ischemia. Stroke 1996;27:1231-35.

Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp (a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59(2):199-204.

Woo J, Lau E, Lam CW, Kay R, Teoh R, Wong HY, et al. Hypertension, lipoprotein (a), and apolipoprotein AI as risk factors for stroke in the Chinese. Stroke. 1991;22(2):203-8.

Zenker G, Költringer P, Bone G, Niederkorn K, Pfeiffer K, Jürgens G. Lipoprotein (a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17(5):942-5.